Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sustained release antiparkinson agents: controlled release levodopa.

S Gauthier1, D Amyot

  • 1McGill Centre for Studies in Aging, Montreal, Quebec, Canada.

The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques
|February 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Observance of antifibrotic treatment in the French OPALE support program for patients with pulmonary fibrosis].

Revue des maladies respiratoires·2026
Same author

Drying Spring Accelerates Transitions Toward Pyrogenic Vegetation in Eastern Boreal North America.

Ecology letters·2025
Same author

Clinical Meaningfulness in Alzheimer's Disease Clinical Trials. A Report from the EU-US CTAD Task Force.

The journal of prevention of Alzheimer's disease·2024
Same author

Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU): Trial Satisfaction and Attitudes towards Future Clinical Trials.

The journal of prevention of Alzheimer's disease..·2024
Same author

Clinical Correlates of the PET-based Braak Staging Framework in Alzheimer's Disease.

The journal of prevention of Alzheimer's disease·2024
Same author

CTAD Task Force Paper: Neuropsychiatric Symptoms in AD: Clinical Trials Targeting Mild Behavioral Impairment: A Report from the International CTAD Task Force.

The journal of prevention of Alzheimer's disease·2024

Sustained-release oral levodopa (Sinemet CR) offers a predictable delivery of medication, stabilizing plasma levels and extending therapeutic effects for Parkinson's disease patients. While effective for motor fluctuations, higher total doses may be needed, and further research is ongoing.

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Parkinson's disease is characterized by motor fluctuations.
  • Standard levodopa therapy can lead to unpredictable plasma levels.
  • Sustained-release formulations aim to improve drug delivery and patient outcomes.

Purpose of the Study:

  • To evaluate the efficacy of sustained-release oral levodopa (Sinemet CR) in managing Parkinson's disease motor fluctuations.
  • To assess the pharmacokinetic profile and tolerability of Sinemet CR.
  • To investigate the potential of early Sinemet CR treatment in delaying or reducing motor fluctuations.

Main Methods:

  • Utilizing Sinemet CR, a prototype sustained-release oral levodopa preparation.
  • Assessing the impact on akinesia periods and motor fluctuations in patients with mild to moderate symptoms.

Related Experiment Videos

  • Monitoring plasma levodopa levels and duration of action.

    • Main Results:

    • Sinemet CR demonstrated efficacy in decreasing akinesia periods.
    • A 10-30% increase in total levodopa dosage was noted due to reduced bioavailability.
    • Increased diphasic dyskinesias were observed towards the end of the day.
    • Good tolerability was reported in de novo patients.

    Conclusions:

    • Sustained-release levodopa (Sinemet CR) provides a slow, predictable delivery, stabilizing plasma levels and prolonging action for Parkinson's patients.
    • While effective for motor fluctuations, dose adjustments and potential for dyskinesias require consideration.
    • Ongoing studies will clarify if early intervention with Sinemet CR impacts the progression of motor fluctuations compared to standard levodopa.